Griffin Deborah A 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 4, 2020

Form 4

Period: 2020-03-02

Chief Accounting Officer

Transactions

Exercise/Conversion
Ordinary Shares
2020-03-02+2,941→ 2,941 total
Sale
Ordinary Shares
2020-03-02$11.60/sh−2,941$34,112→ 0 total
Exercise/Conversion
Ordinary Shares
2020-03-03+1,166→ 1,166 total
Sale
Ordinary Shares
2020-03-03$11.37/sh−1,166$13,253→ 0 total
Exercise/Conversion
Restricted Share Units
2020-03-02−2,941→ 5,882 total
→ Ordinary Shares (2,941 underlying)
Exercise/Conversion
Restricted Share Units
2020-03-03−1,166→ 1,166 total
→ Ordinary Shares (1,166 underlying)

Footnotes (6)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.4600 to $11.7300, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.8900 to $11.7400, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022.
[F6]Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021.

Documents

1 file